A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
详细信息 查看全文
- 作者：Colin D. Weekes (1)
Muralidhar Beeram (2)
Anthony W. Tolcher (2)
Kyriakos P. Papadopoulos (2)
Lia Gore (1)
Priti Hegde (3)
Yan Xin (3)
Ron Yu (3)
L. Mason Shih (3)
Hong Xiang (3)
Rainer K. Brachmann (3)
Amita Patnaik (2) - 关键词：Neuropilin ; 1 ; MNRP1685A ; VEGF ; Clinical trial
- 刊名：Investigational New Drugs
- 出版年：2014
- 出版时间：August 2014
- 年：2014
- 卷：32
- 期：4
- 页码：653-660
- 全文大小：367 KB
- 参考文献：1. Tam SJ, Watts RJ (2010) Connecting vascular and nervous system development: angiogenesis and the blood-brain barrier. Annu Rev Neurosci 33:379鈥?08 w window">CrossRef
2. He Z, Tessier-Lavigne M (1997) Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 90:739鈥?1 w window">CrossRef
3. Soker S, Takashima S, Quan H et al (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735鈥?5 w window">CrossRef
4. Kawasaki T, Kitsukawa T, Bekku Y (1999) A requirement for neuropilin-1 in embryonic vessel formation. Development 126:4895鈥?02
5. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M (2002) Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 277:24818鈥?5 w window">CrossRef
6. Takashima S, Kitakaze M, Asakura M et al (2002) Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A 99:3657鈥?2 w window">CrossRef
7. Gerhardt H, Ruhrberg C, Abramsson A, Fujisawa H, Shima D, Betsholtz C (2004) Neuropilin-1is required for endothelial tip cell guidance in the developing central nervous system. Dev Dyn 231:503鈥? w window">CrossRef
8. Grandclement C, Borg C (2011) Neuropilins: a new target for cancer therapy. Cancers 3:1899鈥?928 w window">CrossRef
9. Bielenberg DR, Pettaway CA, Takashima S et al (2006) Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 312:584鈥?3 w window">CrossRef
10. Beck B, Driessens G, Goossens S et al (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumors. Nature 478:399鈥?03 w window">CrossRef
11. Xin Y, Bai S, Damico-Beyer LA et al (2012) Anti-neuropilin-1 (MRNP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharm Res 29:2512鈥?1 w window">CrossRef
12. Xin Y, Li J, Wu J, et al. (2012b) Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel anti-angiogenesis agent, in two Phase I trials in patients with advanced solid tumors, Clinical Cancer Research, in press.
13. Liang W-C, Dennis MS, Stawicki S et al (2007) Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 366:815鈥?9 w window">CrossRef
14. Pan Q, Chanthery Y, Liang W-C (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11:53鈥?7 w window">CrossRef
15. Bugelski PJ, Achuthanandam R, Capocasale RJ et al (2009) Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 5:499鈥?21 w window">CrossRef
16. Xia CQ, Peng R, Beato F, Clare-Salzler MJ (2005) Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand J Immunol 62:45鈥?4 w window">CrossRef
17. Boks MA, Kager-Groenland JR, Haasjes MS, Zwaginga JJ, van Ham SM, ten Brinke A (2012) IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction鈥揳 comparative study of human clinical-applicable DC. Clin Immunol 142:332鈥?2 w window">CrossRef
18. Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232鈥?1 w window">CrossRef
19. Darbonne WC, Du X, Dhawan P, et al (2011) Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)-treated phase I patients. J Clin Oncol 29
20. Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6:507鈥?8 w window">CrossRef
21. Raja FA, Chopra N, Ledermann JA (2010) Optimal first-line treatment in ovarian cancer. Ann Oncol 23(10):x118鈥搙127
22. Pellet-Many C, Frankel P, Jia H (2008) Neuropilins: structure, function and role in disease. Biochem J 411:211鈥?6 w window">CrossRef
23. Pataik A, LoRusso PM, Messersmith W (2013) A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. (in press) - 作者单位：Colin D. Weekes (1)
Muralidhar Beeram (2)
Anthony W. Tolcher (2)
Kyriakos P. Papadopoulos (2)
Lia Gore (1)
Priti Hegde (3)
Yan Xin (3)
Ron Yu (3)
L. Mason Shih (3)
Hong Xiang (3)
Rainer K. Brachmann (3)
Amita Patnaik (2)
1. University of Colorado School of Medicine and Developmental Therapeutics Program, University of Colorado Cancer Center, Mail Stop 8117, RC1 South, Rm 8123, 12801 E. 17th Avenue, Aurora, CO, 80045, USA
2. South Texas Accelerated Research Therapeutics, San Antonio, TX, USA
3. Genentech Research and Early Development, South San Francisco, CA, USA - ISSN：1573-0646
文摘